Oxaliplatin

Generic Name
Oxaliplatin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C8H14N2O4Pt
CAS Number
61825-94-3
Unique Ingredient Identifier
04ZR38536J
Background

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin.

Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer. This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer.

Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.

Indication

Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.

Associated Conditions
Advanced Colorectal Cancer, Stage III Colon Cancer
Associated Therapies
-

Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29

First Posted Date
2022-02-24
Last Posted Date
2024-07-25
Lead Sponsor
Gruppo Oncologico del Nord-Ovest
Target Recruit Count
63
Registration Number
NCT05253846
Locations
🇮🇹

U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

First Posted Date
2022-02-24
Last Posted Date
2024-11-13
Lead Sponsor
Seagen Inc.
Target Recruit Count
400
Registration Number
NCT05253651
Locations
🇺🇸

Palo Verde Cancer Specialists, Glendale, Arizona, United States

🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

🇺🇸

Pacific Cancer Medical Center, Anaheim, California, United States

and more 229 locations

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

First Posted Date
2022-02-24
Last Posted Date
2022-02-24
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
54
Registration Number
NCT05254899
Locations
🇨🇳

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

First Posted Date
2022-02-23
Last Posted Date
2024-09-30
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
40
Registration Number
NCT05251948
Locations
🇨🇳

The First Affiliated Hospital, Zhejiang University, Hangzhou City, China

🇨🇳

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou City, China

🇨🇳

The General Hospital of People?s Liberation Army (301 Hospital), Beijing City, China

and more 11 locations

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

First Posted Date
2022-02-15
Last Posted Date
2024-12-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
100
Registration Number
NCT05239741
Locations
🇨🇳

The First Affiliated Hospital of Chongqing Medical University ( Site 0051), Chongqing, Chongqing, China

🇨🇳

Beijing Cancer hospital-Digestive Oncology ( Site 0001), Beijing, Beijing, China

🇨🇳

Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 0011), Beijing, Beijing, China

and more 29 locations

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

First Posted Date
2022-02-14
Last Posted Date
2024-01-05
Lead Sponsor
Liangjun Zhu M.M.
Target Recruit Count
38
Registration Number
NCT05237349
Locations
🇨🇳

Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

First Posted Date
2022-02-11
Last Posted Date
2022-08-11
Lead Sponsor
Akeso
Target Recruit Count
130
Registration Number
NCT05235542
Locations
🇨🇳

Shanghai Renji Hospital, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath